Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, talks about how biosimilars have been able to help patients avoid financial toxicity related to oncology care costs.
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, talks about how biosimilars have been able to help patients avoid financial toxicity related to oncology care costs.
Transcript:
What kind of impact have biosimilars made on easing the financial toxicity of cancer treatment, based on your observations and research with the Community Oncology Alliance (COA)?
Biosimilars have had a huge impact within our practice and amongst the COA practices, as shown in our recent biosimilar data project for COA, which supported our working hypothesis that utilization of biosimilars increased access to care and lowered costs to the practices and patients. So, by making the supportive care and therapeutic agents more affordable, we saw a notable increase in access to care, which is patient usage. And in our practice, we saw an average of about a $200 cost savings per treatment for patients when we were able to utilize biosimilars in their treatment plan.
We also saw about a 25% increase in patient access when being able to utilize biosimilars. And we saw this mirrored in our COA data, in which we reviewed about 2.4 million administrations of both innovator as well as biosimilar products, as well as the therapeutic and the supportive care space. So, we saw throughout the whole COA membership, when we looked at that data, it pretty much mirrored what we saw at a practice level, that there was a an increase in access to care and the products, therefore, became more affordable to the practice as well as the patient.
And when you're talking about patient impact and the biosimilar impact on patients, I like to explain it like financing a car. So, the patient's deductible is x and it's always going to be that x, that fixed amount. But when we're considering all of the other patient financial variables, such as food, utilities, and mortgage, utilization of biosimilars can play a large role in whether the patient is satisfying their deductible in a very small 2-month window or being able to spread that out over maybe 6 months or a little bit longer. So, we're spreading out those costs, and thereby, factoring in a decreased financial toxicity or stress to the patient.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen